Companies


ABBA Therapeutics is a privately owned Swiss biotech company established in Basel in 2015. ABBA Therapeutics is committed to developing novel antibody drugs to modulate immune recognition and activation for anti-cancer therapy.

ABBA Therapeutics AG

Hochbergerstrasse 60C

4057 Basel

info@abba-therapeutics.com

abel-systems is a software engineering and IT consulting company specialized in custom web and mobile development. abel-systems develops and distributes the process- and document-management solution QM-Pilot. Furthermore we provide IT solutions for content management, web and mobile apps, as well as the development of individual solutions with modern technologies.

abel-systems

Hochbergerstrasse 60C

4057 Basel

+41 61 205 60 21

info@abel-systems.ch

http://www.abel-systems.ch

Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (esp. hepatocellular carcinoma, HCC). Alentis has in-licensed platform technologies and monoclonal antibodies which are the result of more than a decade of research from University Strasburg / INSERM. The portfolio is based on deep competence in liver diseases and fibrosis and the discovery of a novel, very fundamental mechanism of action underlying these diseases. Alentis has lead monoclonal antibodies which showed consistent compelling efficacy in multiple animal models of fibrosis and liver cancer. Alentis further has a proprietary discovery platform that allows for efficient discovery of compounds and targets that are relevant in the pathology of late stage liver diseases.

Alentis Therapeutics AG

Hochbergerstrasse 60C

4057 Basel

AlloCyte Pharmaceuticals AG

Hochbergerstrasse 60C

4057 Basel

info@allocyte-pharma.com

https://www.allocyte-pharmaceuticals.com

Anaveon AG

Hochbergerstrasse 60C

4057 Basel

Artidis AG focuses on development and commercialization of ARTIDIS (AUTOMATED AND RELIABLE TISSUE DIAGNOSTICS) nanotechnology platform for rapid diagnostics and treatment optimization. ARTIDIS is based on the atomic force microscope, which can determine the (nano)mechanical properties of native tissue by using a fine, nanometer-scale probe. able to examine tissue biopsies within an hour. By providing such nanomechanical profile of patient biopsy sample, ARTIDIS allows for rapid diagnosis of benign or malignant tumors and consequently optimization of treatment for cancer patients.

ARTIDIS AG

Hochbergerstrasse 60C

4057 Basel

Aurealis Pharma is a Swiss-Finnish biopharmaceutical company with a technology platform facilitating combination therapy embedded in one single product that can be administered in a safe, efficient and cost-effective way. Safe food-grade lactic acid bacteria release multiple therapeutic human proteins locally in diseased tissue. Our first products are immuno-therapeutics to treat patients with chronic inflammatory wounds and cancer indications.

Aurealis Pharma AG.

Hochbergerstrasse 60C

4057 Basel

http://www.aurealispharma.com

BioVersys switches off bacterial drug resistance, thus reactivating approved antibiotics.

We develop small chemical molecules, which switch off drug resistance on a gene regulatory level within bacteria, so called TRIC’s (Transcriptional Regulator Inhibitory Compounds). Current pipeline: Gram negative and positive bacteria; Tuberculosis.

BioVersys AG

Hochbergerstrasse 60C

4057 Basel

http://www.bioversys.com

Bottmedical AG is a deep-tech spin-off from the University of Basel based on a IP portfolio related to the core polymer thin-film technology and more than 6 years’ experience in nanotechnology of the founder team. Current commercialization projects relate to flexible micrometer-thin pressure sensor foils and soft electronic human machine Interfaces.

Bottmedical AG

Hochbergerstrasse 60C

4057 Basel

Bottneuro AG develops plant-based, thin-film implants for the spine and brain. Patients suffering from chronic neuropathic pain and Alzheimer’s disease will benefit from our neuromodulation technology. The patented nano-engineered neural interfaces (NENI®) are ultra-thin electrodes with a soft, nano-engineered surface topology. The founder’s team can fall back on several years of experience in polymer nanotechnology, biomaterials, neurosurgery, biotechnology and management.

Bottneuro AG

Hochbergerstrasse 60C

4057 Basel

mail@bottneuro.ch

www.bottneuro.ch

Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 treating patients with multi-drug resistant cancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets.

Cellestia Biotech S.A.

Hochbergerstrasse 60C

4057 Basel

https://www.cellestia.com/

As a global leader in supercomputing, HPE Cray provides highly advanced systems and solutions and world-class service and support to government, industry and academia. HPE Cray technology enables scientists and engineers to not only meet existing and future simulation and analytics challenges but achieve remarkable breakthroughs by accelerating performance, improving efficiency and extending the capabilities of their most demanding applications.

Hewlett Packard Enterprise

Hochbergerstrasse 60C

4057 Basel

https://www.hpe.com/

Di Meliora AG

Hochbergerstrasse 60C

4057 Basel

Edelweiss Connect manages collaborative projects to achieve goals in scientific research, infrastructure development or service provision. Edelweiss Connect acts both as the initiator of independent research projects (eg. in Discovery Informatics, Knowledge Management, Life Sciences, Drug Safety, Environmental Chemistry, Risk Assessment) and as a provider of integrated services for corporate clients in these areas.

Edelweiss Connect GmbH

Hochbergerstrasse 60C

4057 Basel

https://www.edelweissconnect.com

FGen is a service provider for biotechnology, life-sciences, and industry. The company was founded in 2011 by Prof. Sven Panke (Bioprocess Laboratory of the Department of Biosystems Science and Engineering of the ETH Zurich in Basel) and a number of his scientific fellows. FGen develops and performs high throughput experiments and assays on a contract basis for its customers from biotech, pharma, and chemical industries.

FGen GmbH

Hochbergerstrasse 60C

4057 Basel

http://www.fgen.ch

daygnostics AG is delivering solutions for accurate and fast pathogen detections in non-human applications such as food producing industry.

daygnostics AG

Hochbergerstrasse 60C

4057 Basel

www.daygnostics.com (under construction)

Intilaris LifeSciences is a life science company focusing on productivity improvements and optimizations in Clinical development of pharmaceutical companies. The company provides GCP consulting and develops tools and systems that will lead to better utilization of the current resources and optimization of the clinical development processes. The customers of intilaris LifeSciences are the Clinical Development organizations of research oriented pharmaceutical companies. To a wider extend, intilaris LifeSciences servs the Clinical Development organizations of research oriented biotechnology companies as well.

Intilaris LifeSciences GmbH

Hochbergerstrasse 60C

4057 Basel

http://www.intilaris.com

KINARUS AG is a private company located in Basel. We identify and develop differentiated medicines for diseases linked to stress related inflammatory pathways by scientific cross disease area target assessment.

KINARUS AG

Hochbergerstrasse 60C

4057 Basel

http://www.kinarus.com

MOMM Diagnostics GmbH aims to develop a novel in-vitro diagnostic test for the early diagnosis of preeclampsia at the point-of-care. Preeclampsia affects 5-8% of all pregnancies and is one of the top five causes for maternal and infant illness and death. Early identification of the condition is crucial to minimize complications. PE screening, using a simple test for the definite diagnosis at the obstetrician's office helps to save lives and money

MOMM Diagnostics GmbH

Hochbergerstrasse 60C

4057 Basel

https://www.mommdiagnostics.com

NBE-Therapeutics is a new Swiss Life-Sciences company focused on the development of novel antibody-based therapeutics. NBE-Therapeutics utilizes a portfolio of in-house developed, externally acquired, and in-licensed novel patent families for the development of novel, best-in-class antibody drug conjugates (ADCs), that can specifically target cancer cells for destruction.

NBE-Therapeutics GmbH

Hochbergerstrasse 60C

4057 Basel

http://www.NBE-Therapeutics.com

Polyneuron is pioneering a novel therapeutic approach for the effective and safe treatment of antibody-mediated autoimmune diseases of the nervous system where a pathological role of anti-carbohydrate autoantibodies is well established. Polyneuron’s platform focus in on rare but devastating autoimmune diseases of the nervous system with an unmet medical need.

Polyneuron Pharmaceuticals AG

Hochbergerstrasse 60C

4057 Basel

info@polyneuron.com

https://polyneuron.com

Ridgeline is Versant’s newest discovery engine and has laboratories in Basel Technology Park. Ridgeline’s leadership team hails from Roche and has a proven track record in drug development.

Ridgeline Therapeutics AG

Hochbergerstrasse 60C

4057 Basel

Skyhawk Therapeutics, with laboratories in Boston (U.S.) and the Basel Technology Park, is a drug discovery and development company focused on revolutionizing disease treatment with small molecules that correct RNA expression. Our founders are leading experts in developing small molecule therapeutics for RNA-based disease. Our first drug candidates are targeted towards cancers and neurological conditions, some of which were previously considered undruggable.

 

Skyhawk Therapeutics Europe AG

Hochbergerstrasse 60C

4057 Basel

http://www.skyhawktx.com

Sotio Biotech AG

Hochbergerstrasse 60C

4057 Basel

TargImmune Therapeutics AG is a startup company established in March 2016 in Basel, Switzerland. TargImmune is developing a novel cancer-targeted platform technology CTPIC in the field of immuno-oncology and personalized therapy.

TargImmune Therapeutics AG

Hochbergerstrasse 60C

4057 Basel

VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be readily adapted to target a wide range of cancer-related antigens.

Vaximm AG

Hochbergerstrasse 60C

4057 Basel

http://www.vaximm.com

Versameb is a Swiss based biotechnology platform company focusing on the optimized local delivery of therapeutic proteins, currently focusing on applications in regenerative medicine. Our vision is to both improve existing therapies as well as develop transformative therapies in entirely new applications in disease indications of high medial need. Versameb is funded by private international investors. We are committed to create substantial long-term value for our patients, shareholders and other stakeholders.

Versameb AG

Hochbergerstrasse 60C

4057 Basel

https://versameb.com

Success Stories

Edelweiss Connect: Product safety with minimal animal testing

Barry Hardy, CEO of Edelweiss Connect

Artidis: Cancer diagnosis in less than 3 hours

Marija Plodinec, CEO of Artidis

Piqur Therapeutics: Moving on up, but staying close to the Technologiepark Basel

Richard Laube, Executive Chairman of Piqur Therapeutics

NBE Therapeutics: Cancer drugs with a twist for fewer side effects

Ulf Grawunder, CEO of NBE Therapeutics

Cellestia Biotech: At the Technologiepark Basel, you get a plug-and-play set-up, a dynamic environment and first-class infrastructure at an affordable price.

Michael Bauer, CEO of Cellestia Biotech

 

 

Interviews